ERBB2 and cholangiocarcinoma: Additionally, a separate phase II study (NCT04722133) assessed the efficacy of trastuzumab in combination with FOLFOX chemotherapy (folinic acid, 5-fluorouracil, and oxaliplatin) as a second-line treatment in 34 HER2-positive CCA patients, showing an ORR of 29.4%, a median PFS of 5.1 months, and a median OS of 10.7 months [147] (Table 2).